Background: As it is known, long non-coding RNA (lncRNA) affects tumor progression, which has
caused a great upsurge in recent years. It can also affect the growth, migration, and invasion of tumors. The abnormal
expression of lncRNA is associated with malignant tumors. In addition, it has been proved that lncRNA
is a key targeted gene for the treatment of some diseases. PART1, a member of lncRNA, has been reported as a
regulator in the process of tumor occurrence and development. This study aims to reveal the biological functions,
specific mechanisms, and clinical significance of PART1 in various tumor cells.
Methods: Through the careful search of PUBMED, the mechanisms of the effect of PART1 on tumorigenesis
and development are summarized.
Results: On the one hand, the up-regulated expression of PART1 plays a tumor-promoting role in tumors, including
lung cancer, prostate cancer, bladder cancer, and so on. On the other hand, PART1 is down-regulated in
gastric cancer, glioma, and other tumors to play a tumor inhibitory role. In addition, PART1 regulates tumor
growth mainly by targeting microRNA, such as miR-635, directly regulating the expression of proteins, such as
FUS/EZH2, affecting signal pathways, such as Toll-like receptor pathway, or regulating immune cells.
Conclusion: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition,
PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumortargeted